RT Journal Article
SR Electronic
T1 Double blind placebo-controlled trial for the prevention of ulcerative colitis relapses by β-fructan prebiotics: efficacy and metabolomic analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.16.22269376
DO 10.1101/2022.01.16.22269376
A1 Valcheva, Rosica
A1 Armstrong, Heather
A1 Kovic, Ognjen
A1 Bording-Jorgensen, Michael
A1 Veniamin, Simona
A1 Pérez-Muñoz, María Elisa
A1 Haskey, Natasha
A1 Silva, Melissa
A1 Peerani, Farhad
A1 Wong, Karen
A1 Kao, Dina H.
A1 Van Zanten, Sander Veldhuyzen
A1 Kroeker, Karen I.
A1 Gibson, Deanna L.
A1 Wine, Eytan
A1 Gänzle, Michael
A1 Walter, Jens
A1 Dieleman, Levinus A.
YR 2022
UL http://medrxiv.org/content/early/2022/01/18/2022.01.16.22269376.abstract
AB Background Ulcerative colitis (UC) is associated with altered intestinal microbiome (‘dysbiosis’), most significantly, reduced strict butyrate-producing anaerobes and increased facultative anaerobes. Inulin-type prebiotics appear to reduce and prevent colitis in preclinical studies and small clinical trials. However, these results need to be validated in randomized controlled clinical trial (RCT) studies.Aims The aim of this RCT study was to assess the efficacy of β-fructans (oligofructose and inulin) in preventing relapses in UC patients in clinical remission as well as identify potential mechanisms of activity.Methods Adult UC patients in clinical remission (total Mayo score ≤ 2) were randomized to supplement their diet with 15g/d of either β-fructans (oligofructose and inulin; Synergy1/Prebiotin) or placebo (maltodextrin) for 6 months. Partial Mayo scores, medications, adverse events and intervention compliance were monitored monthly. Fecal specimens were collected throughout the study to measure fecal calprotectin (FCP), along with stool metabolites.Results Eighty-nine UC patients in clinical remission were randomized to β-fructans (n=43) or placebo (n=46). Of those, 11 participants never started, 2 were withdrawn, and 76 were included in the study population (β-fructans n=35; placebo n=41). Although there was no difference in symptomatic clinical flare (β-fructans n=11 flare; placebo n=10 flare, P=0.60), patients randomized to oligofructose and inulin showed only a 3-fold median FCP increase versus 17-fold in the placebo group (P=0.038). Interestingly, antibiotics and serotonin reuptake inhibitors significantly increased the relative risk (RR) of flare (RR 3.321, 95% Cl 2.005 to 5.344, P < 0.0001). β-Fructan intake significantly increased anti-inflammatory fecal metabolites (arabinose, L-arabitol, 5-oxo-D-proline).Conclusions Although oligofructose and inulin did not prevent symptomatic relapses in UC patients, their oral administration significantly reduced the severity of biochemical relapse compared to placebo which was further associated with increased anti-inflammatory metabolites.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02865707Funding StatementThe funders had no role in study design, collection, or interpretation of data. The following grants were used to fund the project: Weston Family Foundation Microbiome Initiative (LD). Weston Family Foundation Microbiome Initiative grant (EW, HA, RV, LD). Canadian Institute of Health Research grants (LD, EW). HA was supported by a Canadian Institute of Health Research postdoctoral fellowship. HA and MBJ were supported by Mitacs Elevate fellowships in partner with the Weston Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by Health Research Ethics Board (Study ID Pro00041938) at the University of Alberta and Natural Health Directorate at Health Canada. The study is publicly accessible at the U.S. National Institute of Health database (clinicaltrials.gov identification number NCT02865707).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript